# A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

> **NCT00528333** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 211 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Lintuzumab (SGN-33)
- **DRUG:** Low dose cytarabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00528333
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2015-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528333, "A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00528333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*